Effects of Evolocumab on the Postprandial Kinetics of Apo (Apolipoprotein) B100-and B48-Containing Lipoproteins in Subjects With Type 2 Diabetes

Show full item record



Permalink

http://hdl.handle.net/10138/335991

Citation

Taskinen , MR , Bjornson , E , Kahri , J , Soderlund , S , Matikainen , N , Porthan , K , Ainola , M , Hakkarainen , A , Lundbom , N , Fermanelli , V , Fuchs , J , Thorsell , A , Kronenberg , F , Andersson , L , Adiels , M , Packard , CJ & Boren , J 2021 , ' Effects of Evolocumab on the Postprandial Kinetics of Apo (Apolipoprotein) B100-and B48-Containing Lipoproteins in Subjects With Type 2 Diabetes ' , Arteriosclerosis, Thrombosis, and Vascular Biology , vol. 41 , no. 2 , pp. 962-975 . https://doi.org/10.1161/ATVBAHA.120.315446

Title: Effects of Evolocumab on the Postprandial Kinetics of Apo (Apolipoprotein) B100-and B48-Containing Lipoproteins in Subjects With Type 2 Diabetes
Author: Taskinen, MR; Bjornson, E; Kahri, J; Soderlund, S; Matikainen, N; Porthan, K; Ainola, M; Hakkarainen, A; Lundbom, N; Fermanelli, V; Fuchs, J; Thorsell, A; Kronenberg, F; Andersson, L; Adiels, M; Packard, CJ; Boren, J
Other contributor: University of Helsinki, HUS Medical Imaging Center
University of Helsinki, HUS Internal Medicine and Rehabilitation
University of Helsinki, Clinicum
University of Helsinki, HUS Abdominal Center
University of Helsinki, Doctoral Programme in Clinical Research
University of Helsinki, Research Programs Unit
University of Helsinki, HUS Medical Imaging Center
University of Helsinki, Clinicum








Date: 2021-02
Language: eng
Number of pages: 14
Belongs to series: Arteriosclerosis, Thrombosis, and Vascular Biology
ISSN: 1079-5642
DOI: https://doi.org/10.1161/ATVBAHA.120.315446
URI: http://hdl.handle.net/10138/335991
Abstract: OBJECTIVE: Increased risk of atherosclerotic cardiovascular disease in subjects with type 2 diabetes is linked to elevated levels of triglyceride-rich lipoproteins and their remnants. The metabolic effects of PCSK9 (proprotein convertase subtilisin/kexin 9) inhibitors on this dyslipidemia were investigated using stable-isotope-labeled tracers. APPROACH AND RESULTS: Triglyceride transport and the metabolism of apos (apolipoproteins) B48, B100, C-III, and E after a fat-rich meal were investigated before and on evolocumab treatment in 13 subjects with type 2 diabetes. Kinetic parameters were determined for the following: apoB48 in chylomicrons; triglyceride in VLDL1 (very low-density lipoprotein) and VLDL2; and apoB100 in VLDL1, VLDL2, IDL (intermediate-density lipoprotein), and LDL (low-density lipoprotein). Evolocumab did not alter the kinetics of apoB48 in chylomicrons or apoB100 or triglyceride in VLDL1. In contrast, the fractional catabolic rates of VLDL2-apoB100 and VLDL2-triglyceride were both increased by about 45%, which led to a 28% fall in the VLDL2 plasma level. LDL-apoB100 was markedly reduced by evolocumab, which was linked to metabolic heterogeneity in this fraction. Evolocumab increased clearance of the more rapidly metabolized LDL by 61% and decreased production of the more slowly cleared LDL by 75%. ApoC-III kinetics were not altered by evolocumab, but the apoE fractional catabolic rates increased by 45% and the apoE plasma level fell by 33%. The apoE fractional catabolic rates was associated with the decrease in VLDL2- and IDL-apoB100 concentrations. CONCLUSIONS: Evolocumab had only minor effects on lipoproteins that are involved in triglyceride transport (chylomicrons and VLDL1) but, in contrast, had a profound impact on lipoproteins that carry cholesterol (VLDL2, IDL, LDL).
Subject: apolipoprotein
cardiovascular diseases
chylomicrons
evolocumab
kinetics
TRIGLYCERIDE-RICH LIPOPROTEINS
PCSK9 INHIBITOR EVOLOCUMAB
SUBTILISIN/KEXIN TYPE 9
CARDIOVASCULAR-DISEASE
000 PARTICIPANTS
LDL CHOLESTEROL
REDUCING LIPIDS
EFFICACY
SAFETY
METABOLISM
3121 General medicine, internal medicine and other clinical medicine
Rights:


Files in this item

Total number of downloads: Loading...

Files Size Format View
Effects_of_Evol ... s_With_Type_2_Diabetes.pdf 1.711Mb PDF View/Open

This item appears in the following Collection(s)

Show full item record